Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin

[1]  B. Johansson,et al.  Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. , 2006, Haematologica.

[2]  N. Young,et al.  Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. , 2003, Blood.

[3]  S. Giannouli,et al.  Myelodysplasia‐associated autoimmunity: clinical and pathophysiologic concepts , 2004, European journal of clinical investigation.

[4]  H. Heimpel,et al.  A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes , 2004, Leukemia.

[5]  A. Barrett,et al.  A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. , 2003, Blood.

[6]  L. Genestier,et al.  Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins1 , 2003, Transplantation.

[7]  D. Brennan.  Functional Antibodies to Leukocyte Adhesion Molecules in Antithymocyte Globulins. , 2003 .

[8]  G. Mufti,et al.  A pilot study of antithymocyte globulin (ATG) in the treatment of patients with ‘low‐risk’ myelodysplasia , 2003, British journal of haematology.

[9]  E. Estey,et al.  Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes , 2003, Leukemia.

[10]  N. Young,et al.  Fas-mediated apoptosis is important in regulating cell replication and death in trisomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalities. , 2002, Blood.

[11]  J. Kochenderfer,et al.  Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. , 2002, Blood.

[12]  D. Follmann,et al.  Molecular and flow cytometric characterization of the CD4 and CD8 T‐cell repertoire in patients with myelodysplastic syndrome , 2002, British journal of haematology.

[13]  H. Mayani,et al.  Comparative analysis of the in vitro proliferation and expansion of hematopoietic progenitors from patients with aplastic anemia and myelodysplasia. , 2002, Leukemia research.

[14]  N. Young,et al.  HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. , 2002, Blood.

[15]  N. Young,et al.  Antithymocyte Globulin for Treatment of the Bone Marrow Failure Associated with Myelodysplastic Syndromes , 2002, Annals of Internal Medicine.

[16]  A. Ganser,et al.  Favourable response to antithymocyte or antilymphocyte globulin in low‐risk myelodysplastic syndrome patients with a ‘non‐clonal’ pattern of X‐chromosome inactivation in bone marrow cells , 2002, European journal of haematology.

[17]  B. Cheson,et al.  Report of an international working group to standardize response criteria for myelodysplastic syndromes. , 2000, Blood.

[18]  Y. Saunthararajah,et al.  Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology? , 2000, Seminars in hematology.

[19]  A. Barrett,et al.  Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte‐mediated inhibition of CFU‐GM and alterations in T‐cell receptor Vβ profiles , 1998, British journal of haematology.

[20]  N. Young,et al.  Antithymocyte globulin for patients with myelodysplastic syndrome , 1997, British journal of haematology.

[21]  N. Young,et al.  The pathophysiology of acquired aplastic anemia. , 1997, The New England journal of medicine.

[22]  Hamblin Tj.  Immunological abnormalities in myelodysplastic syndromes. , 1996 .

[23]  H. Mizoguchi,et al.  Response to immunosuppressive therapy and an HLA‐DRB1 allele in patients with aplastic anaemia: HLA‐DRB1*1501 does not predict response to antithymocyte globulin , 1996, British journal of haematology.

[24]  B. Johansson,et al.  Immune‐mediated complications in patients with myelodysplastic syndromes – clinical and cytogenetic features , 1995, European journal of haematology.

[25]  S. Nimer,et al.  An increased HLA DR2 frequency is seen in aplastic anemia patients. , 1994, Blood.

[26]  G. Mufti,et al.  Immunological abnormalities in myelodysplastic syndromes I. SERUM IMMUNOGLOBULINS AND AUTOANTIBODIES , 1986, British journal of haematology.

[27]  D. Machin,et al.  Myelodysplastic syndromes: a scoring system with prognostic significance , 1985, British journal of haematology.

[28]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.